Drug intelligence / Profile preview

TKP-P-02

Development stage: Unknown
Lead developer: TheraCea Pharma
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TKP-P-02 is an 18F-labeled small molecule radiopharmaceutical being developed by TheraCea Pharma as a diagnostic imaging agent for neurological disorders. It is designed for use in Positron Emission Tomography (PET) scans to visualize specific pathological processes in the brain. The drug leverages TheraCea's proprietary radiochemistry platform to enable the rapid and efficient incorporation of the Fluorine-18 isotope into small molecule ligands. It is currently in Phase 2 clinical development for the diagnosis and monitoring of neurological conditions.

Beyond the preview

Go deeper on TKP-P-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKP-P-02.

Explore the full profile